Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

NCT05490043 is registered in ClinicalTrials.gov with Antengene (Hangzhou) Biologics Co., Ltd. as lead sponsor.

NCT NCT05490043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05490043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Lead sponsor
Antengene (Hangzhou) Biologics Co., Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
January 30, 2022
Completion date
March 17, 2025
Enrollment
33 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, mature b-cell non-hodgkin lymphoma, metastatic solid tumor